Soligenix Announces Positive Recommendation by Independent Data Monitoring Committee on its Phase 3 Clinical Trial of SGX301 for the Treatment of Cutaneous T-cell Lymphoma
PRINCETON, N.J., Oct. 15, 2018 -- (Healthcare Sales & Marketing Network) -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where t... Biopharmaceuticals, Oncology Soligenix, hypericin, cutaneous T-cell lymphoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer & Oncology | Clinical Trials | Cutaneous T cell lymphoma | Lymphoma | Marketing | Pharmaceuticals | Rare Diseases | T-cell Lymphoma